Peijia Medical Limited (HKG:9996)

Market Cap	3.81B +44.6%
Revenue (ttm)	731.61M +29.0%
Net Income	-246.75M
EPS	-0.37
Shares Out	669.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	964,000
Average Volume	621,100
Open	5.58
Previous Close	5.65
Day's Range	5.46 - 5.73
52-Week Range	3.72 - 9.36
Beta	0.62
RSI	36.31
Earnings Date	Mar 25, 2026

About Peijia Medical

Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People’s Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company's products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve s...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 1,035
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9996

Financial Performance

In 2024, Peijia Medical's revenue was 615.48 million, an increase of 39.53% compared to the previous year's 441.13 million. Losses were -226.58 million, -42.28% less than in 2023.

Financial numbers in CNY